cyrilzakka/clinical-trials huggingface dataset:
Bilateral Sacroiliac Joint (SIJ) Injection in Lumbar Disc Prolapse

Bilateral sacroiliac joint injection in symptomatic lumbar disc prolapse under ultrasound guidance and studying the effect of this technique on pain, spine mobility and activity of daily living.

86 Patients with lumbar disc prolapse diagnosed by either MRI or CT will be included. All of them aged \> 18 years with no special condition for the duration of disc prolapse. All of them had clinical manifestations in the form of mechanical low back pain or sciatica or limited spine mobility. All participants had no or poor response to conservative treatment. Previous surgery, severe facet arthropathy, ankylosing spondylitis, sensory or motor deficit and wedge fracture were considered as exclusion criteria. Distraction, compression, thigh thrust, and sacral thrust were used to assess SIJ dysfunction only at baseline before injection. Fingertip to floor and Oswestry disability index (ODI) were used to assess mobility and function of the spine at baseline (before and after injection) and after 2 and 16 weeks. Visual Analogue Scale (VAS) was used for pain appraisal at the same intervals. Participants will be randomly assigned into active and control group using 1:1 allocation. In the active group bilateral SIJ injection will be performed under ultrasound US guidance. Under US guidance a 22G spinal needle, where 1 mL 2 % lidocaine hydrochloride (xylocaine, AstraZeneca) mixed with triamcinolone 40 milligrams (Kenacort, Bristol Myers Squip) will be injected in each SIJ.

Eligibility Criteria:
Inclusion Criteria:

* Lumbar disc prolapse diagnosed by either MRI or CT were included.
* All of them aged \> 18 years
* No special condition for the duration of disc prolapse.
* All of them had clinical manifestations in the form of mechanical low back pain or sciatica or limited spine mobility.
* All participants had no or poor response to conservative treatment

Exclusion Criteria:

* Previous surgery
* Severe facet arthropathy
* Ankylosing spondylitis
* Sensory or motor deficit
* Wedge fracture
Personalized Peroral Endoscopic Myotomy for Achalasia

Achalasia is a rare esophageal motility disorder, characterized by incomplete lower esophageal sphincter relaxation, increased Lower esophageal sphincter (LES) tone, and aperistalsis of the esophagus. Typical clinical symptoms are dysphagia,regurgitation and chest pain. Traditional treatments include endoscopic balloon dilatation or botulinum toxin injection, laparoscopic Heller myotomy with or without a partial fundoplication. Peroral endoscopic myotomy (POEM) has been developed as a further endoscopic effective and minimal invasive treatment. The aim of this study is to investigate the efficacy and safety of POEM in our department, and to assess short-term and long-term efficacy of POEM by using Stooler score, Echardt score, esophageal barium and manometry.


Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed as achalasia according to symptoms, esophageal barium,manometry and esophagogastroduodenoscopy
* Age over 18 years old
* Signed written informed consent

Exclusion Criteria:

* Patients with previous surgery of the stomach or esophagus
* With known coagulopathy
* Active esophagitis,eosinophilic esophagitis or Barrett's esophagus
* Pregnancy
* Stricture of the esophagus
* Hiatal hernia \> 2cm
Efficacy of Acupuncture Combined With Moving Cupping and Ear Point Tapping for Moderate and Severe Acne Vulgaris

This trial is designed to evaluate the efficacy of different frequencies in treating the moderate and severe acne vulgaris using acupuncture combined with moving cupping and ear point tapping.

Background: Acne vulgaris is a common skin disease, especially in adolescents and young adults. Acne affects approximately 85% of teenagers, but can occur in most age groups and can persist into adulthood. There is no mortality associated with acne, but there is often significant physical and psychological morbidity. Acupuncture combined with moving cupping and ear point tapping may effectively relieve the skin lesions, but the evidence is limited. Also, young patients usually have no time to see the doctor frequently, thus it's necessary to figure out a better frequency of treating.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosed as acne vulgaris.
* GAGS score between 19 and 38 points.
* Age of 15 to 35 years.

Exclusion Criteria:

* Other types of acne: acne conglobate, acne fulminans，acne medicamentosa, premenstrual acne，cosmetic acne and trade acne.
* Presence of any other systemic disease that could affect the acne severity by its presence, such as polycystic ovarian syndrome, or thyroid diseases, or atypical congenital adrenal hyperplasia；or by any medication prescribed for the treatment of the systemic diseases.

  -- Use of any topical acne treatment or systemic antibiotics or traditional Chinese medicine within 2 weeks before study initiation. Use of a systemic retinoid within 9 months before study initiation. Use of a systemic steroid within 9 months before study initiation. Presence of any change in the use of oral contraceptive pills or anti-inflammatory drugs within 3 months before study initiation.
* Presence of any other skin disease that could interfere with the assessment of the acne, such as folliculitis or rosacea.
* Presence of severe heart, liver, kidney or hematopoietic system diseases, as well as severe malnutrition.
* Pregnancy or lactation.
* Recent use of this research scheme within 4 weeks before study initiation.
Impact of Antiretroviral Treatment on Pharmacokinetics and Pharmacodynamics of Thienopyridines in Healthy Volunteers and HIV Patients

HIV patients are at particular risk to develop cardiovascular disease (CVD) as they exhibit multiple risk factors by the nature of their pathology. In addition, the long term exposition to antiretroviral drugs has been associated to an increased risk for CVD. HIV patients can thus potentially receive antiplatelet therapy concomitantly with their antiretroviral treatment. Clopidogrel and prasugrel are thienopyridine antiplatelet agents indicated to prevent the recurrence of ischemic events after coronary arteries stenting. These pro-drugs are mainly bioactivated by cytochromes P450 (CYP) 3A and 2B6 for prasugrel and CYP2C19, CYP3A and CYP2B6 for clopidogrel. Ritonavir is commonly used to "boost" the bioavailability of other HIV drugs through inhibition of CYP3A4 as well as CYP2B6 and CYP2C9. This interaction could therefore reduce clopidogrel and prasugrel efficacy by reducing the formation of their active metabolites. The aim of the present study is to assess the potential drug-drug interaction between clopidogrel/prasugrel and ritonavir. Two groups of 12 male subjects will be constituted (12 HIV patients under ritonavir boosted therapy and 12 healthy volunteers) in a randomized cross-over clinical trial. All subjects will also be genotyped for the CYP2C19. The pharmacokinetics of clopidogrel active metabolite and prasugrel active metabolite will be assessed. Furthermore, the pharmacodynamic response will be evaluated by two gold standard platelet inhibition tests, namely VAsodilator-Stimulated Phosphoprotein Assay (VASP) and VerifyNow® assays. The primary endpoint of this study is to compare the pharmacodynamic response to clopidogrel and prasugrel in HIV patients to that of healthy volunteers.


Eligibility Criteria:
Inclusion Criteria:

* Healthy males \>18 years
* Understanding of French language and able to give an inform consent
* Anti-HIV therapy with ritonavir or cobicistat (for HIV group)
* Stable antiretroviral treatment since at least 2 weeks (for HIV group)
* Viremia \<100 copies/ml (for HIV group)

Exclusion Criteria:

* renal failure: calculated creatinine Clearance (cockcroft) \< 50ml/min
* hepatic impairment (ASAT, ALAT, bilirubin, gamma-GT more than 2-fold increase)
* smoker \>1 pack/day
* hypersensitivity to any of the drugs used
* intake of any drug or particular food (grapefruit) that can affect CYP activities inhibitors (in the last 10 days before the start of the study or 4 half-life after the last intake)
* pathologies or drugs associated with an increased bleeding risk such as aspirin, non-steroidal anti-inflammatory drugs, steroids and serotonin reuptake inhibitors (in the last 10 days before the start of the study or 4 half-life after the last intake)
* bleeding familial history or antecedent or haemorrhagic disease
Esophageal Hypersensitivity Study in Patients With Gastroesophageal Reflux Disease (GERD)

The purpose of the study is to compare sensitivity of visceral pain in the esophagus using different pain stimuli.


Eligibility Criteria:
Inclusion Criteria:

* Provision of signed informed consent form
* BMI 18.5-35.0, inclusive
* Continuous PPI treatment for GERD during the last 4 weeks

Exclusion Criteria:

* Patients that have not experienced any GERD symptoms improvement at all after PPI treatment
* Unstable or clinically significant disorders including cardiovascular, respiratory, renal, hepatic, metabolic, psychiatric, other gastrointestinal and esophageal disorders besides GERD
* Prior surgery of the upper GI tract
A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics

This study is intended to evaluate the pharmacodynamics, safety, and tolerability of LX4211 when administered concurrently with sitagliptin (Januvia®) in patients with Type 2 Diabetes Mellitus.


Eligibility Criteria:
Inclusion Criteria:

* Adults aged 18 to 65 years of age
* History of Type 2 Diabetes Mellitus for at least 3 months prior to Screening, with HgbA1c values of 6.5 to 10.5% and C-peptide ≥1.0 ng/mL
* Body mass index (BMI) ≤45 kg/sq m
* Willing and able to self-monitor blood glucose
* Able to provide written informed consent

Exclusion Criteria:

* History of Type 1 diabetes mellitus, diabetic ketoacidosis, hyperosmolar nonketotic syndrome, or diabetes resulting from pancreatic disorder or secondary diabetes
* Current use of any blood glucose lowering agent other than metformin
* History of renal disease or clinically significant abnormal kidney function tests at Screening or Day -2
* Presence of active hepatic disease or clinically significant abnormal liver function tests at Screening or Day -2
* History of myocardial infarction, severe/unstable angina, or coronary revascularization procedure within 6 months of Day -2
* History of clinically significant cardiac arrhythmias within 1 year of Day -2
* Congestive heart failure and/or New York Heart Association (NYHA) class III or IV symptoms of heart failure
* Subjects with uncontrolled Stage 3 hypertension
* History of 2 or more emergency room visits, doctor's visits, or hospitalizations due to hypoglycemia within 6 months of Day -2
* History of alcohol or drug abuse within 12 months of Screening
* History of bowel resection \> 20 cm, any malabsorptive disorder, severe gastroparesis, and GI procedure for the purpose of weight loss that would slow gastric emptying
* History of HIV or hepatitis C
* Major surgery within 3 months of Day -2 or any planned surgery during the study
* History of any active infection within 2 weeks of Day -2
* History of pancreatitis
* History of any malignancy within the last 5 years which would affect the diagnosis or assessment of LX4211 or sitagliptin
* History of any serious adverse reaction or hypersensitivity to LX4211 or sitagliptin
* Presence of any clinically significant physical, laboratory, or ECG findings or any concurrent condition at Screening that may interfere with the study in the opinion of the investigator
* Triglycerides \> 1000 mg/dL at Screening or Day -2
* Donation or loss of \>400 mL of blood or blood product within 8 weeks prior to Day -2
* Use of any tobacco product for the duration of study participation
* Use of corticosteroids within 2 weeks of Day 1
* Use of digoxin or warfarin within 2 weeks prior to Screening
Total Hip Replacement With the Answer® Hip Stem and Ranawat/Burnstein® Shell Using Simplex® or Palacos® Bone Cement

The purpose of this study is to document the clinical outcomes of several devices used in total hip replacement, including the Answer® hip stem, the Ranawat/Burnstein® acetabular shell, and Simplex® or Palacos® bone cement.

The purpose of this study is to document the clinical outcomes of several devices used in total hip replacement, including the Answer® hip stem, the Ranawat/Burnstein® acetabular shell, and Simplex® or Palacos® bone cement. It was desirable to see if there were any differences in the outcomes of two different types of bone cement in application.

Eligibility Criteria:
Inclusion Criteria:

* Noninflammatory degenerative joint disease including osteoarthritis and avascular necrosis
* Rheumatoid arthritis
* Correction of functional deformity
* Treatment of non-union, femoral neck fracture, and trochanteric fractures of the proximal femur with head involvement, unmanageable using other techniques

Exclusion Criteria:

* Infection, sepsis, and osteomyelitis
Trial of Continuous Versus Interrupted Feeding for Intubated Intensive Care Unit Patients

Surgical patients fed up until the point of surgery will have safe delivery of more calories compared to a group whose feeding is held at midnight prior to surgery.

Nutrition is essential for healing and recovery from illness. Tube feeds are the standard care for patients with prolonged stays in the intensive care unit (ICU) who cannot eat food on their own. Tube feeding means that a tube has been placed in a patient's stomach or small intestine to provide nutrition.

When a patient is scheduled for an elective surgery, he/she usually has nothing to eat after midnight prior to the operation. A fasting period before surgery is done to avoid possible side effects during the placement of a breathing tube. Having an empty stomach is thought to decrease the chances of vomiting or aspiration while a breathing tube is placed. (Aspiration occurs when a substance, such as food provided by a tube feed, enters the airway.) However, some patients already have a breathing tube in place. The investigators do not know which is better for patients who already have a breathing tube in place: continuing feedings up until surgery or stopping them the night before.

The investigators hypothesize intubated surgical patients randomized to a protocol of feeding up until the point of surgery will have the safe delivery of more calories as compared to a group whose feeding is held at midnight prior to surgery.

Eligibility Criteria:
Inclusion Criteria:

* Intubated with planned visit to the OR
* Admitted to an ICU at OHSU
* Receiving enteral nutrition or plan to start enteral nutrition

Exclusion Criteria:

* Age less than 18 years
* Unable to obtain consent from patient or ARR
Theory-Based Interventions for Smoking and Obesity (Challenge) Trial

The purpose of this study is to examine a new theory for understanding the processes that govern behavior change by observing how people's beliefs and feelings about smoking cessation or weight loss change as they participate in smoking cessation or weight control programs. This study also seeks to improve the ability of treatment programs to help people maintain changes in their behavior.

The goal of this clinical trial is to examine a new theory for understanding the processes that govern short-term versus long-term behavior change. The study will examine how people's beliefs and feelings about smoking cessation or weight loss change as they participate in either a smoking cessation program or a weight control program. Also, the study will improve the ability of treatment programs to help people maintain changes in their behavior. The project involves a series of two parallel investigations.

Study 1 tests the hypothesis that intervention methods that influence cost/benefit expectations related to quitting smoking and losing weight will have different effects on long-term smoking cessation and weight loss. The participants are randomly selected to treatment programs that induce heightened or realistic outcome expectations.

Study 2 tests the hypothesis that intervention methods that influence perceived satisfaction with behavior change will have different effects on long-term smoking cessation and weight loss. The participants are randomly selected to treatment programs that induce them to evaluate the consequences of behavior change either in comparison to past or ideal outcomes.

All of the intervention programs used in these studies are based on highly effective treatment procedures. The programs differ in how information about weight loss and smoking cessation is presented, how the participants are encouraged to think about their achievements during the treatment programs, and how much help is given to the participants in organizing their thoughts during the programs.

Eligibility Criteria:
Eligibility criteria for the smoking cessation studies were: between 18 and 60 years old, a minimum 2-year history of smoking, a current level of smoking \> 10 cigarettes per day, and agreement to participate in the study.

Eligibility requirements for the weight loss studies were: between 18 and 60 years old, body mass index (weight/height2) \> 27.0, 20 percent or more above desirable weight according to medical standards, and consent to participate.

Smokers and overweight persons were excluded if currently being treated by a physician for a serious physical or psychological disorder (e.g., heart disease, cancer, depression). Women were excluded if currently pregnant, pregnant in the last 6 months, or intending to become pregnant in the next 18 months. People who were overweight and who also smoked were considered eligible for participation in either weight loss or smoking cessation programs. However, they received treatment only for the particular behavior problem targeted by the study they chose to participate in.
Human Chorionic Gonadotropin Supplementation Prior to In-vitro Fertilization Treatment in Poor Responders

In an era of delayed fertility plans, there is increasing need for fertility treatment in older women with poor response. Human chorionic gonadotropin (hCG) supplementation prior to treatment, as a thecal stimulant, may improve folliculogenesis and ovarian response.


Eligibility Criteria:
Inclusion Criteria:

* women \>39 years on IVF treatment

Exclusion Criteria:

* polycystic ovary syndrome
* Any allergy to injection of human chorionic gonadotropin before
The Use of Artificial Intelligence in the Dental X-rays Analysis

This cross-sectional study aims to perform a population-based assessment of the incidence of decay, dental fillings, root canal fillings, endodontic lesions, implants, implant and dental abutment crowns, pontic crowns, and missing teeth, taking into account the location.

This cross-sectional study aims to perform a population-based assessment of the incidence of decay, dental fillings, root canal fillings, endodontic lesions, implants, implant and dental abutment crowns, pontic crowns, and missing teeth, considering the location. Patients with indications for dental X-ray confirmed by a written referral and with permanent dentition will participate in the study. Then, the X-rays will be analyzed by the dentists and the AI-based software after the data has been anonymized. The results will be compared to determine the AI algorithm's sensitivity, specificity, and precision.

Eligibility Criteria:
Inclusion Criteria:

* Indications for dental X-ray confirmed by a written referral from the dentist or physician (both screening tests and tests performed for treatment purposes were allowed)
* Permanent dentition (after exfoliation is completed)

Exclusion Criteria:

* Patients with mixed dentition (exfoliation has not finished)
Detection of Microplastics and Nanoplastics in Neurosurgery Patients (DT-MiNi)

Plastic particles are a ubiquitous pollutant in the living environment and food chain, so far, plenty of studies have reported the internal exposure of microplastics and nanoplastics in human tissues and enclosed body fluids.

Neurosurgery is the only department that can open the skull. In addition to blood and cerebrospinal fluid, there are brain tissue and tumors in the presence of lesions. Whether any of these microplastics and nanoplastics are present remains a mystery. This prospective observational study will harvest biological samples of neurosurgery patients.

The objective of this research is to be able to detect microplastics and nanoplastics on blood and operation samples of neurosurgery patients.


Eligibility Criteria:
Inclusion Criteria:

* Age 18-80 years
* Any type of neurosurgery

Exclusion Criteria:

·refusal of the patient to participate
Evaluation of the Impact of a Sugar-Sweetened Beverage Tax in Chile

The purpose of this study is to evaluate formally the short term impacts of the tax policy applied to Sugar-Sweetened Beverages (SSBs) in Chile. The Impuesto Adicional a las Bebidas Analcohólicas (IABA, or "additional tax on soft drinks") in Chile was enacted in October 2014, affecting any non-alcoholic beverages to which colorants, flavourings or sweeteners have been added. For beverages above an added sugar concentration of at least 6.25 grams per 100ml (or equivalent proportion), the tax was increased from 13% to 18%, while for those below this threshold the tax was decreased to 10%, producing an 8% tax difference between these beverage groups. This impact evaluation analysis of the Chilean sugar-sweetened beverage (SSB) tax will estimate the impact of increasing the tax as well as decreasing the tax on soft drinks. The study will use household level grocery purchasing data for Chile. The purchasing records are available from October 2011 to September 2015 (three years before; and one year after the implementation of the tax in October 2014). The investigators will use a series of quasi-experimental approaches to evaluate the causal impact of the SSB tax policy on consumers' behaviour as well as on industry responses in the form of pricing and price promotion decisions.


Eligibility Criteria:
Inclusion Criteria:

* Household in Chile that agreed to participate in the purchasing survey and provided data to a satisfactory degree for the first 2 months.

Exclusion Criteria:

* Households that are unwilling to participate in the survey. Households that change physical address. Households with poor compliance to the survey.